July 26, 2017
BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial
May 24, 2017
Study Shows Helix Transendocardial Delivery System Enables Greater Myocardial Retention of Stem Cell Therapy
April 26, 2017
BioCardia to Present at the 5th Annual Cell & Gene Investor Day
February 28, 2017
Johns Hopkins Medicine, Maryland Stem Cell Research Fund and BioCardia Announce First Patient Treated with CardiAMP Cell Therapy for Ischemic Heart Failure in Phase III Clinical Trial
January 9, 2017
BioCardia to Present at the 9th Annual Biotech Showcase in San Franciscos
December 29, 2016
CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers
December 23, 2016
BioCardia receives another US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program
December 14, 2016
BioCardia receives US Patent covering a method of treating heart attack tissue damage with a patient’s own progenitor cells, providing further protection to Phase III CardiAMP program
November 18, 2016
BioCardia Chairman of the Board Letter to Shareholders
October 24, 2016
BioCardia Closes Merger with Tiger X Medical, Inc.
|
We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.
These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
|
